Figure 5.
Comparative efficacy study in BALB/c nude mice bearing xenografts (PC-3) on tumor growth.
Notes: Treatment started approximately 5 weeks after cell implantation. Mice (n = 5) were administered intravenously with injection of 100 μL of liposome suspensions of DSPC/MonY-BN/Dox, or DSPC/Dox (1.0 × 10−2 M lipid concentration, at a dose of 10 mg of Dox/kg) or 100 μL of HBS buffer (control). Therapeutic efficacy was assessed by measuring tumor volume (mean ± SD) over time. Results were analyzed using two-way analysis of variance, followed by Bonferroni’s test. * denotes P < 0.05 and ** denotes P < 0.01 versus saline. DSPC/MonY-BN/Dox and DSPC/Dox produce, with respect to the saline solution, a TGI of 60% and 36%, respectively.
Abbreviations: BN, bombesin; Dox, doxorubicin; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HBS, HEPES buffered saline; SD, standard deviation; TGI, tumor growth inhibition.